JP2004507460A5 - - Google Patents

Download PDF

Info

Publication number
JP2004507460A5
JP2004507460A5 JP2002501464A JP2002501464A JP2004507460A5 JP 2004507460 A5 JP2004507460 A5 JP 2004507460A5 JP 2002501464 A JP2002501464 A JP 2002501464A JP 2002501464 A JP2002501464 A JP 2002501464A JP 2004507460 A5 JP2004507460 A5 JP 2004507460A5
Authority
JP
Japan
Prior art keywords
disease
cop1
use according
medicament
neuropathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002501464A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004507460A (ja
JP4328090B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/002118 external-priority patent/WO2001093893A2/en
Publication of JP2004507460A publication Critical patent/JP2004507460A/ja
Publication of JP2004507460A5 publication Critical patent/JP2004507460A5/ja
Application granted granted Critical
Publication of JP4328090B2 publication Critical patent/JP4328090B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002501464A 2000-06-07 2001-01-22 神経細胞の保護療法におけるコポリマー1、関連ペプチドおよびポリペプチドならびにそれらによって処理されたt細胞の使用 Expired - Fee Related JP4328090B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20979900P 2000-06-07 2000-06-07
US62021600A 2000-07-20 2000-07-20
PCT/US2001/002118 WO2001093893A2 (en) 2000-06-07 2001-01-22 The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy

Publications (3)

Publication Number Publication Date
JP2004507460A JP2004507460A (ja) 2004-03-11
JP2004507460A5 true JP2004507460A5 (cg-RX-API-DMAC7.html) 2006-02-09
JP4328090B2 JP4328090B2 (ja) 2009-09-09

Family

ID=26904524

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002501464A Expired - Fee Related JP4328090B2 (ja) 2000-06-07 2001-01-22 神経細胞の保護療法におけるコポリマー1、関連ペプチドおよびポリペプチドならびにそれらによって処理されたt細胞の使用

Country Status (16)

Country Link
US (1) US20020037848A1 (cg-RX-API-DMAC7.html)
EP (1) EP1294390B1 (cg-RX-API-DMAC7.html)
JP (1) JP4328090B2 (cg-RX-API-DMAC7.html)
KR (1) KR20030007397A (cg-RX-API-DMAC7.html)
CN (1) CN100438906C (cg-RX-API-DMAC7.html)
AT (1) ATE314860T1 (cg-RX-API-DMAC7.html)
AU (1) AU783031B2 (cg-RX-API-DMAC7.html)
CA (1) CA2398277C (cg-RX-API-DMAC7.html)
CY (1) CY1105263T1 (cg-RX-API-DMAC7.html)
DE (1) DE60116467T2 (cg-RX-API-DMAC7.html)
DK (1) DK1294390T3 (cg-RX-API-DMAC7.html)
ES (1) ES2256200T3 (cg-RX-API-DMAC7.html)
IL (2) IL150801A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02007109A (cg-RX-API-DMAC7.html)
NZ (1) NZ520282A (cg-RX-API-DMAC7.html)
WO (1) WO2001093893A2 (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
EP1098902A4 (en) 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
CA2411536A1 (en) * 2000-06-05 2001-12-13 V. Wee Yong The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
EP1459065B1 (en) 2001-12-04 2010-07-28 Teva Pharmaceutical Industries, Ltd. Processes for the measurement of the potency of glatiramer acetate
US7351686B2 (en) * 2001-12-06 2008-04-01 Yeda Research And Development Co. Ltd. Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides
WO2004060265A2 (en) * 2003-01-07 2004-07-22 Yeda Research And Development Co. Ltd. Eye-drop vaccine containing copolymer 1 for therapeutic immunization
CN1886506B (zh) * 2003-09-29 2012-05-30 中外制药株式会社 在nk细胞中表达的蛋白质
WO2005032482A2 (en) * 2003-10-03 2005-04-14 Bayhill Therapeutics, Inc. Treatment of demyelinating autoimmune disease with modified ordered peptides
CA2546077C (en) * 2003-11-12 2016-07-05 Yeda Research And Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
DK1701730T3 (da) * 2003-12-09 2013-11-25 Yeda Res & Dev Fremgangsmåde og vaccine omfattende copolymer 1 til behandling af psykiatriske forstyrrelser
CA2565819A1 (en) 2004-05-07 2005-12-01 Peptimmune, Inc. Methods of treating disease with random copolymers
DK1799703T3 (da) 2004-09-09 2010-04-19 Teva Pharma Fremgangsmåde til fremstilling af blandinger af polypeptider ved hjælp af oprenset hydrogenbromid
ES2541780T3 (es) * 2004-11-29 2015-07-24 Yeda Research And Development Co., Ltd. Inducción de la neurogénesis y terapia con células madre en combinación con el Copolímero 1
JP2009536157A (ja) 2006-04-13 2009-10-08 ペプチミューン,インコーポレイテッド エピトープ透過性の指向された拡張を介した指向性配列ポリマー組成物の設計方法および合成方法
WO2009040814A1 (en) 2007-09-24 2009-04-02 Hadasit Medical Research Services & Development Ltd Use of copolymer 1 for treatment of muscular dystrophy
AP3467A (en) 2007-10-16 2015-11-30 Peptimmune Inc Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes
WO2009063459A2 (en) * 2007-11-13 2009-05-22 Yeda Research And Development Co. Ltd Synthetic peptide copolymers for treatment of neurodevelopmental disorders
RS55607B1 (sr) 2009-08-20 2017-06-30 Yeda Research & Development Company Ltd Niskofrekventna terapija glatiramer acetatom
WO2011080733A1 (en) 2010-01-04 2011-07-07 Mapi Pharma Limited Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
EA025780B1 (ru) 2010-10-11 2017-01-30 Тева Фармасьютикал Индастриз Лтд. Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
MX2014004309A (es) 2011-10-10 2015-07-06 Teva Pharma Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer.
EP2892353A4 (en) 2012-09-10 2016-10-26 Yeda Res & Dev INDIVIDUALIZED IMMUNOMODULATION THERAPY FOR NEURODEGENERATIVE ILLNESSES, CNS LESIONS AND AGGREGATIVE DEMENTIA
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
IL316573A (en) 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis
EP4340853A4 (en) * 2021-05-20 2025-05-07 Washington University Neuroprotective compositions and methods
KR20230128606A (ko) * 2022-02-28 2023-09-05 경상국립대학교산학협력단 티로신을 유효성분으로 함유하는 알츠하이머병의 예방, 개선 또는 치료용 조성물
CN121517513A (zh) * 2025-11-20 2026-02-13 西湖大学 一种共聚物多肽及其药物组合物和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
JP2002503658A (ja) * 1998-02-13 2002-02-05 オートイミューン インク COP−1及びTh−2促進性サイトカインを使用した、多発性硬化症の治療

Similar Documents

Publication Publication Date Title
Hohlfeld et al. The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis
Bakalash et al. Antigenic specificity of immunoprotective therapeutic vaccination for glaucoma
JP2003520246A5 (cg-RX-API-DMAC7.html)
Schwartz Macrophages and microglia in central nervous system injury: are they helpful or harmful?
Mizrahi et al. The tissue-specific self-pathogen is the protective self-antigen: the case of uveitis
US9517256B2 (en) Vaccine and method for treatment of neurodegenerative diseases
CN100438906C (zh) 共聚物1和相关肽和多肽及其处理过的t细胞在保护cns细胞避免谷氨酸毒性中的用途
Hendrix et al. The role of T helper cells in neuroprotection and regeneration
JP2003532618A5 (cg-RX-API-DMAC7.html)
HK1054507B (zh) 共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途
Born et al. Role of gammadelta T cells in protecting normal airway function
TWI804521B (zh) Tau胜肽免疫原結構
AU2007264682B2 (en) Method of treatment of age-related macular degeneration
JP2003518507A5 (cg-RX-API-DMAC7.html)
JP4542339B2 (ja) 運動ニューロン疾患を治療するためのワクチン及び方法
CA2451521A1 (en) Use of poly-glu, tyr for neuroprotective therapy
He et al. Glatiramer acetate reverses cognitive deficits from cranial-irradiated rat by inducing hippocampal neurogenesis
JP5291878B2 (ja) 治療的免疫のためのコポリマー1を含む点眼ワクチン
PH12021552683A1 (en) Heterologous administration of tau vaccines
von Euler Chelpin et al. Targets and mechanisms in prevention of Parkinson's disease through immunomodulatory treatments
US20090191173A1 (en) Induction Of Neurogenesis And Stem Cell Therapy In Combination With Copolymer 1
Palumbo et al. Immunomodulation induced by central nervous system‐related peptides as a therapeutic strategy for neurodegenerative disorders
García et al. The severity of spinal cord injury determines the inflammatory gene expression pattern after immunization with neural-derived peptides
Mantzourani et al. Structural requirements for binding of myelin basic protein (MBP) peptides to MHC II: effects on immune regulation
Wang et al. Enhanced expression of neurotrophic factors in the injured spinal cord through vaccination with myelin basic protein-derived peptide pulsed dendritic cells